Navigation Links
Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico
Date:12/15/2011

CALGARY, Alberta, Dec. 15, 2011 /PRNewswire/ -- Fero Industries, Inc. (OTCQB: FROI), announced today that Pharmaroth S.A., the Company's Mexican operating subsidiary, has completed the registration process to become a pharmaceutical Certified Supplier to federal and local government institutions within Mexico. This license, which is the first in a series of certifications, allows the Company to provide coverage to PEMEX (Petroleos Mexicanos), the Mexican State-owned oil company with over 500,000 current and retired employees who are eligible for healthcare benefits. The Company's ability to supply its product to PEMEX provides a substantial new source of potential customers for Sucanon® as well as other pharmaceutical products.

"We are extremely excited to have achieved the first Certified Supplier status in Mexico, as it allows Pharmaroth to sell Sucanon® and other products to the hundreds of thousands of people who receive healthcare through PEMEX," stated Luis Lopez, President and COO of Fero Industries. "PEMEX is one of the most prestigious names in corporate Mexico, and to be able to directly supply their employees and their families with Sucanon® is a very big milestone for Fero."

The Company is continuing the process to become a Certified Supplier to other federal and local government institutions, including the Instituto Nacional de Nutrición, the Instituto Nacional de Cancerología (INCAN), Secretaría de Salud del Distrito Federal, to reach over 2,500,000 potential new customers that receive their primary healthcare through these low-cost public government healthcare offices.

Sucanon® is approved as an over-the-counter ("OTC") remedy for type-2 diabetes by regulatory authorities in Mexico and is distributed there under an exclusive agreement with Merck S.A. de C.V.  (Merck S.A. de C.V. is the Mexico and Latin America sales and marketing organization of German pharmaceutical and chemical giant, Merck KGaA.)  

Commercial sales of Sucanon® began in January 2011 in Mexico.  Mexico has one of the largest and fastest growing diabetic populations in the world, estimated at 15% of the total population. This indicates over 16 million diagnosed cases of diabetes, up seven fold since 1990.  Diabetes is now the leading cause of death in Mexico and costs the country more than one-third of its total public health care budget annually.

About Sucanon®
Sucanon® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers."  Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin.  Sucanon® has been approved for prescription sale in China and Peru.  Sucanon® is also approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.

For further information regarding Sucanon®, please visit the Fero Industries, Inc. website at www.feroindustries.com, email us at mike@parvise.com

About Fero Industries, Inc.
Fero Industries, Inc. (OTCQB: FROI) is focused on diabetes prevention and treatments.  The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for type-2 diabetes.  Sucanon® is a member of a class of diabetic medications called insulin sensitizers.  Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin.  Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.  Fero's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

For investor relations contact:
Michael Irving 
Paramount Advisors, LLC
(407) 878-5462

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions.  Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Fero Industries, Inc. (the Company) to be materially different from those expressed or implied by such forward-looking statements.

The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov under "Search for Company Filings."


'/>"/>
SOURCE Fero Industries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
2. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
3. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
4. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
7. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
8. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
11. CureDMs Diabetes Therapy Achieves Major Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... /PRNewswire/ - Demers Ambulances announces its first delivery in the state ... County Emergency Medical Services (EMS) consisting of four ... van. Quality Emergency Vehicles in Lecanto, FL ... This is the latest in Demers, ongoing expansion of sales.  ... Demers. --> Benoit LaFortune , Executive Vice President ...
(Date:2/12/2016)... Feb. 12, 2016   HeartWare International, Inc . ... and webcast to discuss its financial results for the ... Thursday, February 25, 2016 at 8:00 a.m. ET.  The ... the conference call and webcast.  On the conference call ... highlights from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Tech Outlook’s top Clinical Data Management Solution Providers list for its expertise in ... functional and domain expertise to serve the technology needs of global clients. DDi ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan ... The purpose of these scholarships is to encourage applicants to pursue a degree in ... within these two parishes. , “We have available jobs in St. Landry and ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
Breaking Medicine News(10 mins):